Palembang City

Researchers are evaluating the effectiveness of the tetravalent dengue vaccine (TDV) in reducing hospital stays due to dengue virus infections among children and adolescents in Southeast Asian countries with high dengue transmission, specifically Thailand, Indonesia, and Malaysia. This study focuses on participants aged 6 to 12 years who are part of a community-based cohort and may or may not receive TDV as part of a pilot public vaccination program. The research aims to provide further information on TDV's effectiveness, especially against the less common dengue virus types DENV-3 and DENV-4. This is a non-interventional study where participants are observed over a period of three years. Some cohort members may receive the TDV vaccine as part of a public vaccination program, while others may not be vaccinated. Researchers will compare hospitalization rates due to dengue between vaccinated and unvaccinated participants, without administering any study-specific treatments or interventions. Participants will be followed individually for three years, with their health monitored to identify any hospital stays caused by dengue infections. Blood samples may be collected at baseline and during illness episodes to confirm dengue infection using laboratory tests like RT-PCR. The primary outcome measured is hospitalization due to virologically confirmed dengue of any serotype. The study also includes matched case-control analyses within the cohort to better understand vaccine effectiveness and safety.

The HYIMPACT study is a large, observational research project across seven Asian countries designed to understand how Nebilet (nebivolol) works in people with high blood pressure, also called hypertension. It focuses on how Nebilet affects blood pressure control over time, treatment adherence, quality of life, prescription habits, and heart-related outcomes. The study includes about 5,000 adults with newly diagnosed or uncontrolled hypertension, some of whom may have other heart-related conditions. Participants will either start Nebilet treatment or have been on it for no more than two weeks before joining. They will be observed regularly for up to three years, with blood pressure measurements taken at baseline, 12, 24, and 36 months. The study also compares Nebilet used alone versus in combination with other treatments, and examines the relationship between blood pressure readings taken at home and in the clinic. Throughout the study, patients will have their blood pressure monitored, complete questionnaires about medication adherence and quality of life, and provide health information including cardiovascular risk factors and lab test results when available. Researchers will track major heart events like heart attacks and strokes, and record any side effects. Data will be collected electronically to ensure quality and consistency, helping to provide real-world insights about Nebilet's role in managing hypertension over time.